Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 4Prostatic Neoplasms 2Venous Thromboembolism 1Thrombocythemia, Essential 1Smoking Cessation 1Primary Myelofibrosis 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasms 1Motor Activity 1Lung Neoplasms 1Liver Cirrhosis 1Leukemia, Hairy Cell 1Inflammation 1Hemorrhage 1Fibrosis 1Fallopian Tube Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Carcinoma 1Breast Neoplasms 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 22Bevacizumab 20Carboplatin 19liposomal doxorubicin 14Specimen Handling 14Magnetic Resonance Spectroscopy 13olaparib 12Topotecan 9Gemcitabine 9Biopsy 8pembrolizumab 7Taxes 6Immunoglobulin G 6Disulfides 6niraparib 4mirvetuximab soravtansine 4cediranib 4Doxorubicin 4oregovomab 3Nivolumab 3Cyclophosphamide 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Oxaliplatin 2Docetaxel 2Cisplatin 2Biosimilar Pharmaceuticals 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Aspirin × 90 days × Clear all
NCT05080946 2026-04-01

Using Aspirin to Improve Immunological Features of Ovarian Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Recruiting
100 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡